Patents by Inventor Gérald Perret
Gérald Perret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190002537Abstract: Disclosed is a method for preparing an immunoglobulin (Ig) concentrate useful for treating RSV infection, including a step consisting in subjecting an Ig composition derived from blood plasma to affinity chromatography utilizing an RSV-specific ligand. In a particular embodiment, the RSV-specific ligand is an RSV F protein, preferentially in prefusion conformation, or a variant or an antigenic fragment thereof.Type: ApplicationFiled: September 30, 2016Publication date: January 3, 2019Inventors: Gèrald PERRET, Abdessatar CHTOUROU
-
Patent number: 9803184Abstract: The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6.Type: GrantFiled: December 30, 2011Date of Patent: October 31, 2017Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Egisto Boschetti, Gérald Perret
-
Patent number: 9534012Abstract: An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.Type: GrantFiled: February 19, 2010Date of Patent: January 3, 2017Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Gerald Perret, Michel Nogre
-
Patent number: 9359610Abstract: A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form.Type: GrantFiled: July 30, 2010Date of Patent: June 7, 2016Assignee: Laboratoire Français du Fractionnement et des BiotechnologiesInventors: Gerald Perret, Sami Chtourou, Nicolas Bihoreau
-
Patent number: 9347052Abstract: The invention relates to nucleic acid aptamers binding specifically to factor H, to a method for obtaining same, and to the uses thereof, in particular for the purposes of purifying factor H.Type: GrantFiled: November 28, 2012Date of Patent: May 24, 2016Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Gerald Perret, Agnes Cibiel
-
Publication number: 20160009761Abstract: The invention relates to a method for purifying or detecting a target protein present in a solution, wherein said method comprises, before carrying out the purification or detection step itself, the step of contacting said solution with an aptamer binding specifically to said target protein, wherein said aptamer does not bind to any protein homologous to said target protein that could also be present in the solution.Type: ApplicationFiled: September 22, 2015Publication date: January 14, 2016Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Laurent Siret, Abdessatar Chtourou, Frederic Dhainaut, Gerald Perret
-
Patent number: 9175034Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.Type: GrantFiled: August 13, 2008Date of Patent: November 3, 2015Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Laurent Siret, Abdessatar Chtourou, Frédéric Dhainaut, Gérald Perret
-
Publication number: 20140329289Abstract: The invention relates to nucleic acid aptamers binding specifically to factor H, to a method for obtaining same, and to the uses thereof, in particular for the purposes of purifying factor H.Type: ApplicationFiled: November 28, 2012Publication date: November 6, 2014Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Gerald Perret, Agnes Cibiel
-
Patent number: 8790881Abstract: A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: a) preparing a sample A of immunoglobulin G and a sample B including natural serum, the natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams):(volume of natural serum in B in liters) of between and 75, at a temperature of between 2° C. and 6° C., and subsequently incubating the resulting reaction mixture at a temperature of between 35° C. and 40° C. for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0° C. and 4° C. in the presence of EDTA; and d) measuring the amount of C5a fragment in the cooled reaction mixture obtained in c).Type: GrantFiled: May 4, 2011Date of Patent: July 29, 2014Assignee: Laboratoire francais du Fractionnement et des BiotechnologiesInventors: Frederic Dhainaut, Gerald Perret
-
Publication number: 20130344567Abstract: The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6.Type: ApplicationFiled: December 30, 2011Publication date: December 26, 2013Applicant: LFB BiotechnologiesInventors: Egisto Boschetti, Gérald Perret
-
Patent number: 8608961Abstract: The present invention is directed to an affinity chromatography column comprising the antithrombin III (ATIII) protein bound to a solid support, characterized in that: a. the ATIII protein is the wild-type protein or a variant thereof, b. the ATIII protein has been first activated by incubation with an unmodified low-molecular-weight heparin (LMWH) rich in active species, and c. the ATIII protein is covalently bound to a resin in a ratio of less than approximately 2 mg of protein per ml of hydrated resin. The invention is also directed to the use of the aforesaid column for purifying species having an affinity for ATIII in a sample comprising species having affinity and not having affinity for ATIII.Type: GrantFiled: January 28, 2008Date of Patent: December 17, 2013Assignee: Aventis Pharma S.A.Inventors: Pierre Mourier, Gerald Perret
-
Publication number: 20130143302Abstract: A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form.Type: ApplicationFiled: July 30, 2010Publication date: June 6, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Sami Chtourou, Nicolas Bihoreau
-
Publication number: 20130052659Abstract: A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: a) preparing a sample A of immunoglobulin G and a sample B including natural serum, the natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams):(volume of natural serum in B in liters) of between and 75, at a temperature of between 2° C. and 6° C., and subsequently incubating the resulting reaction mixture at a temperature of between 35° C. and 40° C. for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0° C. and 4° C. in the presence of EDTA;and d) measuring the amount of C5a fragment in the cooled reaction mixture obtained in c).Type: ApplicationFiled: May 4, 2011Publication date: February 28, 2013Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frederic Dhainaut, Gerald Perret
-
Publication number: 20120122179Abstract: An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.Type: ApplicationFiled: February 19, 2010Publication date: May 17, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Michel Nogre
-
Publication number: 20120041056Abstract: A nucleic acid includes at least 15 nucleotides with a length specifically binding with the human factor VII/VIIa.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Frederic Duconge
-
Publication number: 20120040905Abstract: An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Michel Nogre
-
Publication number: 20110097715Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.Type: ApplicationFiled: August 13, 2008Publication date: April 28, 2011Applicant: LFB - BIOTECHNOLOGIESInventors: Laurent Siret, Abdessatar Chtourou, Frédéric Dhanaut, Gérald Perret
-
Publication number: 20080188650Abstract: The present invention is directed to an affinity chromatography column comprising the antithrombin III (ATIII) protein bound to a solid support, characterized in that: a. the ATIII protein is the wild-type protein or a variant thereof, b. the ATIII protein has been first activated by incubation with an unmodified low-molecular-weight heparin (LMWH) rich in active species, and c. the ATIII protein is covalently bound to a resin in a ratio of less than approximately 2 mg of protein per ml of hydrated resin. The invention is also directed to the use of the aforesaid column for purifying species having an affinity for ATIII in a sample comprising species having affinity and not having affinity for ATIII.Type: ApplicationFiled: January 28, 2008Publication date: August 7, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Pierre MOURIER, Gerald PERRET